Expertise in
29
conditions

Dr. Susan Iannaccone

Pediatrics
University Of Texas Southwestern Medical Center
5323 Harry Hines Blvd, 
Dallas, TX 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
29
conditions
University Of Texas Southwestern Medical Center
5323 Harry Hines Blvd, 
Dallas, TX 

Overview

Susan Iannaccone is a Pediatrics provider in Dallas, Texas. Dr. Iannaccone is highly rated in 29 conditions, according to our data. Her top areas of expertise are Spinal Muscular Atrophy (SMA), Primary Lateral Sclerosis, Spinal Muscular Atrophy Type 2, Thymectomy, and Gastrostomy.

Her clinical research consists of co-authoring 72 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Pediatrics

Licenses

Psychiatry & Neurology in TX

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 4 Less Insurance Carriers -

Locations

University of Texas Southwestern Medical Center
5323 Harry Hines Blvd, Dallas, TX 75390

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Prospective, Long-Term Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
A Prospective, Long-Term Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
Enrollment Status: Recruiting
Publish Date: January 31, 2025
Intervention Type: Drug, Other
A Global Study of a Single, One-Time Dose of AVXS-101 Delivered to Infants With Genetically Diagnosed and Pre-symptomatic Spinal Muscular Atrophy With Multiple Copies of SMN2
A Global Study of a Single, One-Time Dose of AVXS-101 Delivered to Infants With Genetically Diagnosed and Pre-symptomatic Spinal Muscular Atrophy With Multiple Copies of SMN2
Enrollment Status: Completed
Publish Date: January 26, 2026
Intervention Type: Biological
Study Drug: Onasemnogene Abeparvovec-Xioi
Study Phase: Phase 3
Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion
Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion
Enrollment Status: Completed
Publish Date: January 26, 2026
Intervention Type: Biological
Study Phase: Phase 3
Phase I, Open-Label, Dose Comparison Study of AVXS-101 for Sitting But Non-ambulatory Patients With Spinal Muscular Atrophy
Phase I, Open-Label, Dose Comparison Study of AVXS-101 for Sitting But Non-ambulatory Patients With Spinal Muscular Atrophy
Enrollment Status: Terminated
Publish Date: January 26, 2026
Intervention Type: Biological
Study Phase: Phase 1
A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: November 18, 2025
Intervention Type: Drug
Study Drugs: SRP-4045 Exon 45-Skipping Treatment, SRP-4053 Exon 53-Skipping Treatment
Study Phase: Phase 3
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Intravenous Delivery of Allogeneic Cardiosphere-Derived Cells in Subjects With Duchenne Muscular Dystrophy
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Intravenous Delivery of Allogeneic Cardiosphere-Derived Cells in Subjects With Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: May 28, 2025
Intervention Type: Drug, Biological
Study Phase: Phase 2
Trial of Pamrevlumab (FG-3019), a Monoclonal Antibody to Connective Tissue Growth Factor, in Non-Ambulatory Subjects With Duchenne Muscular Dystrophy
Trial of Pamrevlumab (FG-3019), a Monoclonal Antibody to Connective Tissue Growth Factor, in Non-Ambulatory Subjects With Duchenne Muscular Dystrophy
Enrollment Status: Terminated
Publish Date: August 27, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 2
An Open-Label, Multi-Center, Study With a Concurrent Untreated Control Arm to Evaluate the Efficacy and Safety of Eteplirsen in Duchenne Muscular Dystrophy
An Open-Label, Multi-Center, Study With a Concurrent Untreated Control Arm to Evaluate the Efficacy and Safety of Eteplirsen in Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: January 25, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Ataluren (PTC124®) in Patients Aged ≥2 to <5 Years Old With Nonsense Mutation Dystrophinopathy
A Phase 2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Ataluren (PTC124®) in Patients Aged ≥2 to <5 Years Old With Nonsense Mutation Dystrophinopathy
Enrollment Status: Completed
Publish Date: August 28, 2020
Intervention Type: Drug
Study Phase: Phase 2
Phase 2 Historically Controlled Trial of Corticosteroids in Young Boys With Duchenne Muscular Dystrophy
Phase 2 Historically Controlled Trial of Corticosteroids in Young Boys With Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: December 21, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

72 Total Publications

Taking on the Titin: Muscle imaging as a diagnostic marker of biallelic TTN-related myopathy.
Taking on the Titin: Muscle imaging as a diagnostic marker of biallelic TTN-related myopathy.
Journal: Journal of neuromuscular diseases
Published: February 19, 2025
Similar Doctors
Expertise in
39
conditions
Dr. Bruce J. Schlomer
Pediatrics | Urology
Expertise in
39
conditions
Dr. Bruce J. Schlomer
Pediatrics | Urology

Texas Scottish Rite Hospital For Children

2222 Welborn St, 
Dallas, TX 
 (0.1 miles away)
214-559-5000
Languages Spoken:
English
See accepted insurances

Bruce Schlomer is a Pediatrics specialist and a Urologist in Dallas, Texas. Dr. Schlomer is highly rated in 39 conditions, according to our data. His top areas of expertise are Testicular Torsion, Hypospadias, Neurogenic Bladder, Reconstructive Urology Surgery, and Gastrostomy.

Micah A. Jacobs
Expertise in
29
conditions
Dr. Micah A. Jacobs
Pediatrics | Urology
Expertise in
29
conditions
Dr. Micah A. Jacobs
Pediatrics | Urology

Texas Scottish Rite Hospital For Children

2222 Welborn St, 
Dallas, TX 
 (0.1 miles away)
214-559-5000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Micah Jacobs is a Pediatrics specialist and a Urologist in Dallas, Texas. Dr. Jacobs is highly rated in 29 conditions, according to our data. His top areas of expertise are Testicular Torsion, Neurogenic Bladder, Undescended Testicle, Orchiectomy, and Ureteral Reconstruction.

Expertise in
17
conditions
Dr. Jennifer Cao
Pediatrics
Expertise in
17
conditions
Dr. Jennifer Cao
Pediatrics

University Of Texas Southwestern Medical Center

5323 Harry Hines Blvd, 
Dallas, TX 
 (1.6 miles away)
214-648-3848
Languages Spoken:
English
See accepted insurances

Jennifer Cao is a Pediatrics provider in Dallas, Texas. Dr. Cao is highly rated in 17 conditions, according to our data. Her top areas of expertise are Cicatricial Pemphigoid, Scleritis, Uveitis, and Neuroretinitis.

Frequently Asked Questions about Dr. Susan Iannaccone

How do I make an appointment with Dr. Susan Iannaccone?

You can book an appointment with Dr. Susan Iannaccone by calling their office at 214-456-2768. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Susan Iannaccone a top-rated expert for Spinal Muscular Atrophy (SMA)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Susan Iannaccone is classified as an Elite expert for Spinal Muscular Atrophy (SMA), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Susan Iannaccone specialize in?

While Dr. Susan Iannaccone is a Pediatrics, they have specific expertise in Spinal Muscular Atrophy (SMA), Primary Lateral Sclerosis, and Spinal Muscular Atrophy Type 2. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Pediatrics.

Does Dr. Susan Iannaccone participate in research or clinical trials?

Yes. Dr. Susan Iannaccone has published 72 articles and abstracts on conditions like Spinal Muscular Atrophy (SMA). You can view a list of Dr. Susan Iannaccone's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Susan Iannaccone accept my insurance?

Dr. Susan Iannaccone accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 214-456-2768 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Iannaccone's expertise for a condition
ConditionClose
View All 21 Advanced Conditions
View All 60 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile